Last reviewed · How we verify
Sps (SODIUM POLYSTYRENE SULFONATE)
Sodium Polystyrene Sulfonate (Sps) is a potassium binder originally developed by Concordia Pharms Inc and currently owned by Concordia. It is a small molecule drug that works by exchanging sodium ions for potassium ions in the gastrointestinal tract, thereby reducing potassium levels in the blood. Sps is approved to treat hyperkalemia and is available as a generic medication, with 14 generic manufacturers. It was first approved by the FDA in 1958 and is no longer patented. As a potassium binder, Sps is a critical medication for managing high potassium levels in patients with kidney disease or other conditions.
At a glance
| Generic name | SODIUM POLYSTYRENE SULFONATE |
|---|---|
| Sponsor | Concordia |
| Drug class | Potassium Binder [EPC] |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1958 |
Approved indications
- Hyperkalemia
Common side effects
- Fecal impaction
- Gastrointestinal concretions (bezoars)
- Ischemic colitis
- Gastrointestinal tract ulceration or necrosis
- Intestinal perforation
- Acute bronchitis
- Broncho-pneumonia
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Hypokalemia
Key clinical trials
- Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®) (NA)
- Comparison of Potassium Binders in the ER (PHASE4)
- OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (PHASE2)
- Recovery After Dialysis-Requiring Acute Kidney Injury (NA)
- SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients (NA)
- The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels (NA)
- Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
- Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sps CI brief — competitive landscape report
- Sps updates RSS · CI watch RSS
- Concordia portfolio CI